Pacific Biosciences Of California, Inc. revenue
Pacific Biosciences Of California, Inc.'s revenue was $160m in fiscal 2025, up 3.9% on the year before. Since fiscal 2009 ($135,000) it has grown at a compound 55.6% a year. Over the last twelve months it was $159m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2 | 34 | 26 | 28 | 61 | 93 | 91 | 93 | 79 | 91 | 79 | 131 | 128 | 201 | 154 | 160 | 159 |
| Growth on the year before | — | +>999% | +>999% | −23.3% | +8.5% | +115.0% | +53.1% | −2.2% | +3.0% | −15.9% | +15.6% | −13.2% | +65.4% | −1.7% | +56.3% | −23.2% | +3.9% | — |
| Gross profit | 0 | 2 | 13 | 1 | 6 | 23 | 53 | 44 | 35 | 25 | 35 | 33 | 59 | 49 | 53 | 37 | 46 | 58 |
| Gross margin | 100.0% | 100.0% | 38.5% | 3.6% | 22.8% | 38.6% | 57.6% | 48.7% | 37.1% | 31.9% | 38.0% | 41.3% | 45.1% | 38.2% | 26.3% | 24.2% | 28.6% | 36.4% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $136M | 84.8% | ▼ 0.3% |
| Consumable (part of Products) | $81.9M | 60.4% | ▲ 16.4% |
| Instrument (part of Products) | $53.8M | 39.6% | ▼ 18.2% |
| Service and Other | $24.2M | 15.2% | ▲ 35.7% |
| Region | Revenue | YoY |
|---|---|---|
| Americas | $72.8M | ▼ 7.5% |
| United States | $69.7M | ▼ 7.4% |
| EMEA | $44.1M | ▲ 27.3% |
| Asia Pacific | $43.2M | ▲ 6.0% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Pacific Biosciences Of California, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Pacific Biosciences Of California, Inc. | $159m | 2.0% | 2.9% |
| Grail, Inc. | $165m | 23.1% | — |
| Quanterix Corp | $153m | 22.0% | 11.1% |
| Cryoport, Inc. | $186m | 12.1% | -8.2% |
| Cytek Biosciences, Inc. | $207m | 5.4% | 5.6% |
| Maravai Lifesciences Holdings, Inc. | $209m | -5.0% | -27.3% |
Compare with peers
- Grail, Inc. revenue
- Quanterix Corp revenue
- Cryoport, Inc. revenue
- Cytek Biosciences, Inc. revenue
- Maravai Lifesciences Holdings, Inc. revenue
Head to head: GRAL vs PACBPACB vs QTRXCYRX vs PACB
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies